Short-Term Effects of a Multimodal 3-Week Inpatient Pulmonary Rehabilitation Programme for Patients with Sarcoidosis: The ProKaSaRe Study

Respiration

Volumn 95, Issue 5, 2018, Pages 343-353

  Lingner, Heidrun ^a,b   Buhr Schinner, Heike ^c   Hummel, Stefan ^d   Van Der Meyden, Jochen ^e   Grosshennig, Anika ^f   Nowik, Daniel ^a   Schultz, Konrad ^g  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b German Center for Lung Research   (Germany)

^c Department of Internal Medicine Pneumology   (Germany)

^d MEDIAN Kliniken GmbH   (Germany)

^e Klinik Wehrawald   (Germany)

^f MH Hannover   (Germany)

^g Klinik Bad Reichenhall   (Germany)

Author keywords

Fatigue; Pulmonary rehabilitation; Quality of life; Sarcoidosis

Indexed keywords

ADULT; AGED; ANXIETY; ARTICLE; DEPRESSION; DYSPNEA; FATIGUE; FEMALE; HOSPITAL PATIENT; HUMAN; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; SIX MINUTE WALK TEST; TREATMENT OUTCOME; VITAL CAPACITY; CLINICAL TRIAL; EXERCISE TEST; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGED; EXERCISE TEST; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SARCOIDOSIS, PULMONARY; YOUNG ADULT;

EID: 85042714139     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000486964     Document Type: Article

References (53)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS), and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999: 160: 736-755.
2. Bosse-Henk A, Koch R, Wirtz H, Hinz A: Fatigue and excessive daytime sleepiness in sarcoidosis: prevalence, predictors, and relationships between the two symptoms. Respiration 2017; 94: 186-197.
3. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K, Holland AE, Lareau SC, Man WD, et al: An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188:e13-e64.
4. Osadnik CR, Rodrigues FMM, Camillo CA, Loeckx M, Janssens W, Dooms C, Troosters T: Grundlagen der Rehabilitation und Reaktivierung. Karger Kompass Pneumol 2016; 4: 8-17.
5. Langer D: Rehabilitation in patients before and after lung transplantation. Respiration 2015; 89: 353-362.
6. Burtin C, Hebestreit H: Rehabilitation in patients with chronic respiratory disease other than chronic obstructive pulmonary disease: exercise and physical activity interventions in cystic fibrosis and non-cystic fibrosis bronchiectasis. Respiration 2015; 9: 181-189.
7. Dreher M, Ekkernkamp E, Schmoor C, Schoenheit-Kenn U, Winterkamp S, Kenn K: Pulmonary rehabilitation and noninvasive ventilation in patients with hypercapnic interstitial lung disease. Respiration 2015; 89: 208-213.
8. Holland AE, Dowman LM, Hill CJ: Principles of rehabilitation and reactivation: interstitial lung disease, sarcoidosis and rheumatoid disease with respiratory involvement. Respiration 2015; 89: 89-99.
9. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF: Short-term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63: 549-554.
10. Dowman L, Hill CJ, Holland AE: Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2014; 10: CD006322.
11. Ferreira A, Garvey C, Connors GL, Hilling L, Rigler J, Farrell S, Cayou C, Shariat C, Collard HR: Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest 2009; 135: 442-447.
12. Huppmann P, Sczepanski B, Boensch M, Winterkamp S, Schonheit-Kenn U, Neurohr C, Behr J, Kenn K: Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J 2013; 42: 444-453.
13. Marcellis RG, Lenssen AF, de Vries J, Drent M: Reduced muscle strength, exercise intolerance and disabling symptoms in sarcoidosis. Curr Opin Pulm Med 2013; 19: 524-530.
14. Marcellis RG, Lenssen AF, Elfferich MD, De Vries J, Kassim S, Foerster K, Drent M: Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011; 38: 628-634.
15. Spruit MA, Thomeer MJ, Gosselink R, Troosters T, Kasran A, Debrock AJ, Demedts MG, Decramer M: Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60: 32-38.
16. Drent M, Marcellis R, Lenssen A, De Vries J: Association between physical functions and quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 117-128.
17. Strookappe B, Swigris J, De Vries J, Elfferich M, Knevel T, Drent M: Benefits of physical training in sarcoidosis. Lung 2015; 193: 701-708.
18. Marcellis R, Van der Veeke M, Mesters I, Drent M, De Bie R, De Vries G, Lenssen A: Does physical training reduce fatigue in sarcoidosis? Sarcoidosis Vasc Diffuse Lung Dis 2015; 32: 53-62.
19. Strookappe B, Saketkoo LA, Elfferich M, Holland A, De Vries J, Knevel T, Drent M: Physical activity and training in sarcoidosis: review and experience-based recommendations. Expert Rev Respir Med 2016; 10: 1057-1068.
20. Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
21. Baughman RP, Sparkman BK, Lower EE: Sixminute walk test and health status assessment in sarcoidosis. Chest 2007; 132: 207-213.
22. De Vries J, Drent M: Quality of life and health status in sarcoidosis: a review of the literature. Clin Chest Med 2008; 29: 525-532.
23. Jones PW: Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19: 398-404.
24. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, McCormack MC, Carlin BW, Sciurba FC, Pitta F, et al: An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014; 44: 1428-1446.
25. Alhamad EH: The six-minute walk test in patients with pulmonary sarcoidosis. Ann Thorac Med 2009; 4: 60-64.
26. Bullinger M: German translation and psychometric testing of the SF-36 Health Survey: preliminary results from the IQOLA Project. International Quality of Life Assessment. Soc Sci Med 1995; 41: 1359-1366.
27. De Vries J, Michielsen H, Van Heck GL, Drent M: Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004; 9: 279-291.
28. Herrmann C, Buss U, Snaith RP: HADS-D-Hospital Anxiety and Depression Scale-Deutsche Version: Ein Fragebogen zur Erfassung von Angst und Depressivitat in der somatischen Medizin. Bern, Huber, 1995.
29. Criee CP, Berdel D, Heise D, Kardos P, Kohler D, Leupold W, Magnussen H, Marek W, Merget R, Mitfessel H, et al: Recommendations on spirometry by Deutsche Atemwegsliga (in German). Pneumologie 2006; 60: 576-584.
30. Criee CP: Whole-body plethysmography (in German). Med Klin (Munich) 2010; 105: 652-660.
31. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-586.
32. Lieberman J: Elevation of serum angiotensinconverting-enzyme (ACE) level in sarcoidosis. Am J Med 1975; 59: 365-372.
33. Lingner H, Grosshennig A, Flunkert K, Buhr-Schinner H, Heitmann R, Tonnesmann U, van der Meyden J, Schultz K: ProKaSaRe Study Protocol: a prospective multicenter study of pulmonary rehabilitation of patients with sarcoidosis. JMIR Res Protoc 2015; 4:e134.
34. Scadding JG: Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J 1961; 2: 1165-1172.
35. de Kleijn WP, De Vries J, Wijnen PA, Drent M: Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med 2011; 105: 1388-1395.
36. Enright PL, Sherrill DL: Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998; 158: 1384-1387.
37. Bourbonnais JM, Malaisamy S, Dalal BD, Samarakoon PC, Parikh SR, Samavati L: Distance saturation product predicts healthrelated quality of life among sarcoidosis patients. Health Qual Life Outcomes 2012; 10: 67.
38. Kabitz HJ, Lang F, Walterspacher S, Sorichter S, Muller-Quernheim J, Windisch W: Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest 2006; 130: 1496-1502.
39. Alhamad EH, Shaik SA, Idrees MM, Alanezi MO, Isnani AC: Outcome measures of the 6 minute walk test: relationships with physiologic and computed tomography findings in patients with sarcoidosis. BMC Pulm Med 2010; 10: 42.
40. Marcellis RG, Lenssen AF, Kleynen S, De Vries J, Drent M: Exercise capacity, muscle strength, and fatigue in sarcoidosis: a followup study. Lung 2013; 191: 247-256.
41. Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, Gramm M, Hummler S, Brunnemer E, Kreuter M, Watz H: Clinical correlates of reduced physical activity in idiopathic pulmonary fibrosis. Respiration 2016; 91: 497-502.
42. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA: Health-related quality of life of persons with sarcoidosis. Chest 2004; 125: 997-1004.
43. Gvozdenovic BS, Mihailovic-Vucinic V, Ilic-Dudvarski A, Zugic V, Judson MA: Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med 2008; 102: 1636-1642.
44. Antoniou KM, Tzanakis N, Tzouvelekis A, Samiou M, Symvoulakis EK, Siafakas NM, Bouros D: Quality of life in patients with active sarcoidosis in Greece. Eur J Intern Med 2006; 17: 421-426.
45. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y: Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 2:CD003793.
46. Karadalli MN, Bosnak-Guclu M, Camcioglu B, Kokturk N, Turktas H: Effects of inspiratory muscle training in subjects with sarcoidosis: a randomized controlled clinical trial. Respir Care 2016; 61: 483-494.
47. Drent M, Lower EE, De Vries J: Sarcoidosisassociated fatigue. Eur Respir J 2012; 40: 255-263.
48. Hinz A, Fleischer M, Brahler E, Wirtz H, Bosse-Henck A: Fatigue in patients with sarcoidosis, compared with the general population. Gen Hosp Psychiatry 2011; 33: 462-468.
49. de Kleijn WP, De Vries J, Lower EE, Elfferich MD, Baughman RP, Drent M: Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 2009; 15: 499-506.
50. Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA, Drent M: Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-? treatment. Respiration 2010; 80: 212-219.
51. Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, Gramm M, Hummler S, Brunnemer E, Kreuter M, Watz H: Clinical correlates of reduced physical activity in idiopathic pulmonary fibrosis. Respiration 2016; 91: 497-502.
52. Osadnik CR, Rodrigues FMM, Camillo CA, Loeckx M, Janssens W, Dooms C, Troosters T: Principles of rehabilitation and reactivation. Respiration 2015; 89: 2-11.
53. Schultz K, Seidl H, Jelusic D, Wagner R, Wittmann M, Faller H, Nowak D, Schuler M: Effectiveness of pulmonary rehabilitation for patients with asthma: study protocol of a randomized controlled trial (EPRA). BMC Pulm Med 2017; 17: 49-59.